Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Boehringer Ingelheim (Germany) · Boehringer Ingelheim (Austria)
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
863
total citations
- FWCI
- 28.88
- Percentile
- 100%
- References
- 39
Citations per year
Authors
10- FSFlavio SolcaCorresponding
Boehringer Ingelheim (Germany), Boehringer Ingelheim (Austria)
- GDG. Dahl
Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany)
- AZAndreas Zoephel
Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany)
- GBGerd Bader
Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany)
- MPMichael P. Sanderson
Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany)
Topics & keywords
Topics
Keywords
- Afatinib
- Epidermal growth factor receptor
- ErbB
- T790M
- Receptor
- Chemistry
- EGFR inhibitors
- Acrylamide
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.